These services aim to reduce variability and improve reproducibility for various downstream applications, including disease modeling, drug discovery, toxicology screening, and regenerative medicine research. The collaboration will make it easier for pluripotent stem cell researchers to characterize new or existing cell lines and create fully characterized banks of hPSCs, according to both organizations.

Initially, the services only will be offered in the U.S.

Stemcell, Hubrecht to partner on noncancer organoids
Stemcell Technologies and Hubrecht Organoid Technology have signed an agreement to use tissue-derived organoids for preclinical toxicology screening and...